carlisle medical
Refill Requests shipment tracking contact carlisle medical
Knowledge Center
Industrial related news
DEA Proposes Reduction in Manufacturing of Opioids for 2018
Released: 08/07/2017
By: Heidi Dufrene, PharmD

The DEA has proposed to reduce the manufacturing of controlled substances in the United States for 2018 by 20% when compared to 2017. The change is due to a decrease in the demand of opioids such as oxycodone, hydrocodone, oxymorphone, hydromorphone, codeine, fentanyl, meperidine and morphine, according to sales data from IMS Health.

The DEA uses this sales data along with several other factors to determine the yearly APQ, or Aggregate Production Quota, for controlled substances. According to the DEA, this APQ reflects the total amount of controlled substances needed to meet the United States' medical, scientific, research, industrial, export, and reserve needs for the year. Once the DEA sets the Aggregate Production Quota, it can allocate individual quotas to manufacturers. This individual quota can be revised any time during the year if changes in the market warrant an increase in production.

<<Back
 
Company News
Generic Releases
Industry Related News
Industry Related Links
Newsletter Subscription
Newsletter Login
 
 
 
 
 
© Copyright 2018 Carlisle Medical, Inc.
Twitter Twitter Twitter Twitter
disclaimer site map disclaimer